AU5197986A - Transmissible, mammalian genes associated with tumor metastasis - Google Patents
Transmissible, mammalian genes associated with tumor metastasisInfo
- Publication number
- AU5197986A AU5197986A AU51979/86A AU5197986A AU5197986A AU 5197986 A AU5197986 A AU 5197986A AU 51979/86 A AU51979/86 A AU 51979/86A AU 5197986 A AU5197986 A AU 5197986A AU 5197986 A AU5197986 A AU 5197986A
- Authority
- AU
- Australia
- Prior art keywords
- cells
- metastasis
- dna
- tumor
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 129
- 206010027476 Metastases Diseases 0.000 title claims description 100
- 230000009401 metastasis Effects 0.000 title claims description 72
- 206010028980 Neoplasm Diseases 0.000 title claims description 58
- 210000004027 cell Anatomy 0.000 claims description 144
- 108020004414 DNA Proteins 0.000 claims description 120
- 239000003550 marker Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 49
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 46
- 230000001394 metastastic effect Effects 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 29
- 238000001890 transfection Methods 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 108091023043 Alu Element Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 230000003042 antagnostic effect Effects 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 230000008485 antagonism Effects 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 47
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 238000011081 inoculation Methods 0.000 description 17
- 108700020796 Oncogene Proteins 0.000 description 13
- 108700042226 ras Genes Proteins 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 206010005003 Bladder cancer Diseases 0.000 description 8
- 201000001531 bladder carcinoma Diseases 0.000 description 8
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 6
- 102100029974 GTPase HRas Human genes 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 241000880621 Ascarina lucida Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000007099 Yamamoto allylation reaction Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 101150038738 ble gene Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000018529 duodenal adenocarcinoma Diseases 0.000 description 1
- 201000005839 duodenum adenocarcinoma Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67662584A | 1984-11-30 | 1984-11-30 | |
| US676625 | 1991-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5197986A true AU5197986A (en) | 1986-06-18 |
Family
ID=24715276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU51979/86A Abandoned AU5197986A (en) | 1984-11-30 | 1985-11-26 | Transmissible, mammalian genes associated with tumor metastasis |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049662A (en) * | 1987-10-13 | 1991-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Kit for diagnosing cancer metastatic potential |
| ES2164634T3 (es) * | 1989-10-18 | 2002-03-01 | Us Health | Produccion y uso de proteina nm23-h2 humana y anticuerpos previstos a tal efecto. |
| US6825320B1 (en) | 1995-03-29 | 2004-11-30 | Millenium Pharmaceuticals, Inc. | FOHY03 polypeptides |
| US6251597B1 (en) | 1996-03-29 | 2001-06-26 | Millennium Pharmaceuticals, Inc. | Methods for detecting fohy030 |
| US6794185B1 (en) | 1995-03-29 | 2004-09-21 | Millennium Pharmaceuticals, Inc. | fohy030 nucleic acid molecules |
| US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
| US5783182A (en) * | 1996-01-30 | 1998-07-21 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| DE69630142D1 (de) * | 1995-11-16 | 2003-10-30 | Baylor College Medicine | Verfahren zur identifizierung metastatischer sequenzen |
| USRE38490E1 (en) | 1995-11-16 | 2004-04-06 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| WO1997025443A1 (en) * | 1996-01-10 | 1997-07-17 | The University Of Liverpool | Metastasis inducing dna's |
| USRE38392E1 (en) | 1996-01-30 | 2004-01-20 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| US6312909B1 (en) | 1996-03-29 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis prevention and treatment of tumor progression |
| WO1999022773A2 (en) | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| EP1062340A2 (en) | 1998-03-13 | 2000-12-27 | The Baylor College of Medicine | Compositions and methods for the treatment and prevention of metastatic disorders |
| US7462491B2 (en) | 2002-01-31 | 2008-12-09 | Baylor College Of Medicine | Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin |
-
1985
- 1985-11-26 IL IL77157A patent/IL77157A0/xx unknown
- 1985-11-26 JP JP60505382A patent/JPS62501399A/ja active Pending
- 1985-11-26 FI FI863095A patent/FI863095A0/fi not_active IP Right Cessation
- 1985-11-26 HU HU8667A patent/HUT41837A/hu unknown
- 1985-11-26 WO PCT/US1985/002323 patent/WO1986003226A1/en not_active Application Discontinuation
- 1985-11-26 AU AU51979/86A patent/AU5197986A/en not_active Abandoned
- 1985-11-26 EP EP85906133A patent/EP0203970A1/en not_active Withdrawn
- 1985-11-27 ZA ZA859070A patent/ZA859070B/xx unknown
- 1985-11-27 GR GR852864A patent/GR852864B/el unknown
- 1985-11-29 ES ES549438A patent/ES8705043A1/es not_active Expired
- 1985-11-29 PT PT81584A patent/PT81584B/pt unknown
-
1986
- 1986-07-29 NO NO863066A patent/NO863066L/no unknown
- 1986-07-29 DK DK359486A patent/DK359486A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI863095L (fi) | 1986-07-29 |
| FI863095A7 (fi) | 1986-07-29 |
| DK359486D0 (da) | 1986-07-29 |
| HUT41837A (en) | 1987-05-28 |
| ES8705043A1 (es) | 1987-04-16 |
| EP0203970A1 (en) | 1986-12-10 |
| PT81584B (en) | 1987-04-07 |
| DK359486A (da) | 1986-07-29 |
| NO863066L (no) | 1986-09-29 |
| GR852864B (enrdf_load_stackoverflow) | 1986-03-28 |
| ZA859070B (en) | 1986-07-30 |
| IL77157A0 (en) | 1986-04-29 |
| JPS62501399A (ja) | 1987-06-11 |
| ES549438A0 (es) | 1987-04-16 |
| NO863066D0 (no) | 1986-07-29 |
| FI863095A0 (fi) | 1986-07-29 |
| PT81584A (en) | 1985-12-01 |
| WO1986003226A1 (en) | 1986-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mulligan et al. | Factors governing the expression of a bacterial gene in mammalian cells | |
| AU5197986A (en) | Transmissible, mammalian genes associated with tumor metastasis | |
| US4663290A (en) | Production of reverse transcriptase | |
| Shih et al. | Isolation of a transforming sequence from a human bladder carcinoma cell line | |
| Smithies et al. | Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination | |
| EP0518650B1 (en) | Sequence specific DNA binding by P53 | |
| US5814476A (en) | Process for the production of stochastically-generated transcription or translation products | |
| Snyder et al. | [7] λgt 11: Gene isolation with antibody probes and other applications | |
| EP0174810B1 (en) | Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna | |
| EP0346710B1 (en) | cDNAs coding for members of the carcinoembryonic antigen family | |
| EP0241961A2 (en) | Assay for carcinogenesis caused by oncogenes | |
| Clayton et al. | Cloning and characterization of the integrated viral DNA from three lines of SV40-transformed mouse cells | |
| Young et al. | Bacteriophage T4 gene transcription studied by hybridization to cloned restriction fragments | |
| US4725550A (en) | Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma | |
| Fang et al. | Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma | |
| Lee et al. | Structural alterations in the long terminal repeat of an acquired mouse mammary tumor virus provirus in a T-cell leukemia of DBA/2 mice | |
| US4818694A (en) | Production of herpes simplex viral protein | |
| JP3256227B2 (ja) | Ｄｎａプローブの開発およびヒト腫瘍関連抗原の免疫学的試薬 | |
| Polvino-Bodnar et al. | Construction and characterization of viable deletion mutants of simian virus 40 lacking sequences near the 3′ end of the early region | |
| Stanners et al. | Cloning of a functional gene responsible for the expression of a cell surface antigen correlated with human chronic lymphocytic leukemia | |
| Fisher et al. | Wilms' tumor-aniridia association: segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene | |
| Ruddle et al. | DNA-mediated gene transfer in mammalian gene cloning | |
| Wang et al. | Polymerization of vector DNA after transfection into hamster fibroblast cells | |
| EP0873424B1 (en) | Metastasis inducing dna's | |
| US6159751A (en) | Development of DNA probes and immunological reagents of human tumor associated antigens |